• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

全胃切除术后单剂量地诺单抗治疗胃癌弥漫性骨转移后出现的持续性低钙血症

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.

作者信息

Iizumi Sakura, Shimoi Tatsunori, Nishikawa Tadaaki, Kitano Atsuko, Sasada Shinsuke, Shimomura Akihiko, Noguchi Emi, Yunokawa Mayu, Yonemori Kan, Shimizu Chikako, Fujiwara Yasuhiro, Tamura Kenji

机构信息

Department of Breast and Medical Oncology, National Cancer Center Hospital, Japan.

Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan.

出版信息

Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.

DOI:10.2169/internalmedicine.8908-17
PMID:28943574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5709630/
Abstract

Hypocalcemia is a significant adverse effect of denosumab. We herein report a case of prolonged hypocalcemia in a patient with multiple risk factors for hypocalcemia, including gastrectomy, increased bone turnover, and a poor performance status. Hypocalcemia developed after denosumab treatment for diffuse bone metastasis of gastric cancer, despite oral supplementation with vitamin D and calcium. To avoid serious prolonged hypocalcemia, a thorough assessment of the bone calcium metabolism is required before initiating denosumab treatment.

摘要

低钙血症是地诺单抗的一种显著不良反应。我们在此报告一例低钙血症患者出现长时间低钙血症的病例，该患者存在多种导致低钙血症的危险因素，包括胃切除术、骨转换增加和身体状况较差。尽管口服补充了维生素D和钙，但在使用地诺单抗治疗胃癌弥漫性骨转移后仍出现了低钙血症。为避免严重的长时间低钙血症，在开始使用地诺单抗治疗前需要对骨钙代谢进行全面评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a38a/5709630/fc22f3659ea8/1349-7235-56-2879-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a38a/5709630/031984b53e14/1349-7235-56-2879-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a38a/5709630/fc22f3659ea8/1349-7235-56-2879-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a38a/5709630/031984b53e14/1349-7235-56-2879-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a38a/5709630/fc22f3659ea8/1349-7235-56-2879-g002.jpg

相似文献

1
Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.全胃切除术后单剂量地诺单抗治疗胃癌弥漫性骨转移后出现的持续性低钙血症
Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.
2
Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.转移性乳腺癌伴弥漫性骨累及患者单次使用地舒单抗后出现严重且持久的低钙血症，且无钙/维生素 D 补充。
J Oncol Pharm Pract. 2021 Jul;27(5):1287-1290. doi: 10.1177/1078155220964550. Epub 2020 Oct 21.
3
Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.地舒单抗致低钙血症风险分析：在严格的地舒单抗给药管理系统中，补充钙剂/维生素 D 时，肾功能不全不是其发生的危险因素。
Biol Pharm Bull. 2021;44(12):1819-1823. doi: 10.1248/bpb.b21-00653.
4
A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.RANKL的一个问题：地诺单抗诱导的低钙血症。
J Med Toxicol. 2016 Sep;12(3):305-8. doi: 10.1007/s13181-016-0543-y. Epub 2016 Mar 17.
5
Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis.在接受地诺单抗预防骨转移中骨相关事件的患者中低钙血症的发生率。
J Oncol Pharm Pract. 2017 Apr;23(3):179-184. doi: 10.1177/1078155216628325. Epub 2016 Jun 23.
6
High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.高血清碱性磷酸酶水平与实体瘤骨转移患者中地诺单抗相关低钙血症风险增加有关。
Endocr J. 2016 May 31;63(5):479-84. doi: 10.1507/endocrj.EJ16-0003. Epub 2016 Feb 9.
7
Organic anxiety in a woman with breast cancer receiving denosumab.患有乳腺癌并接受地舒单抗治疗的女性的有机性焦虑。
Gen Hosp Psychiatry. 2015 Mar-Apr;37(2):192.e7-8. doi: 10.1016/j.genhosppsych.2015.01.007. Epub 2015 Feb 2.
8
Development of Risk Prediction Model for Grade 2 or Higher Hypocalcemia in Patients With Bone Metastasis Treated With Denosumab Plus Cholecalciferol (Vitamin D )/Calcium Supplement.地舒单抗联合胆钙化醇（维生素 D）/钙补充剂治疗骨转移患者中 2 级或更高等级低钙血症的风险预测模型的建立。
J Clin Pharmacol. 2022 Sep;62(9):1151-1159. doi: 10.1002/jcph.2057. Epub 2022 May 2.
9
Hypocalcaemia in patients with metastatic bone disease treated with denosumab.伴有骨质转移的患者接受地舒单抗治疗后发生低钙血症。
Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17.
10
Use and safety of denosumab in cancer patients.地诺单抗在癌症患者中的应用与安全性。
Int J Clin Pharm. 2017 Jun;39(3):522-526. doi: 10.1007/s11096-017-0455-1. Epub 2017 Apr 5.

引用本文的文献

1
Severe denosumab-induced hypocalcemia requiring long-term intensified medication in a patient with -mutant lung cancer and diffuse osteoblastic bone metastases.在一名患有 - 突变肺癌和弥漫性成骨性骨转移的患者中，地诺单抗诱导的严重低钙血症需要长期强化药物治疗。
Respir Med Case Rep. 2025 Feb 26;54:102183. doi: 10.1016/j.rmcr.2025.102183. eCollection 2025.
2
A DRAMATIC RESPONSE TO DENOSUMAB: PROTRACTED HYPOCALCEMIA RELATED TO HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE 1-ASSOCIATED ADULT T-CELL LEUKEMIA/LYMPHOMA.地诺单抗的显著反应：与人类T细胞嗜淋巴细胞病毒1型相关的成人T细胞白血病/淋巴瘤相关的持续性低钙血症
AACE Clin Case Rep. 2019 Apr 25;5(3):e210-e213. doi: 10.4158/ACCR-2018-0479. eCollection 2019 May-Jun.

本文引用的文献

1
Long-term pharmacotherapy considerations in the bariatric surgery patient.肥胖症手术患者的长期药物治疗考量
Am J Health Syst Pharm. 2016 Aug 15;73(16):1230-42. doi: 10.2146/ajhp151062. Epub 2016 Jun 28.
2
High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors.高血清碱性磷酸酶水平与实体瘤骨转移患者中地诺单抗相关低钙血症风险增加有关。
Endocr J. 2016 May 31;63(5):479-84. doi: 10.1507/endocrj.EJ16-0003. Epub 2016 Feb 9.
3
Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
伴有骨质转移的患者接受地舒单抗治疗后发生低钙血症。
Eur J Cancer. 2015 Sep;51(13):1812-21. doi: 10.1016/j.ejca.2015.05.016. Epub 2015 Jun 17.
4
Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.地诺单抗在肾功能不全的转移性实体瘤患者中的耐受性。
Support Care Cancer. 2015 Jun;23(6):1657-62. doi: 10.1007/s00520-014-2521-8. Epub 2014 Nov 25.
5
Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.因分泌甲状旁腺激素相关蛋白（PTHrP）的神经内分泌肿瘤导致的恶性肿瘤体液性高钙血症患者，单次注射地诺单抗后出现持续性低钙血症。
Clin Endocrinol (Oxf). 2014 Dec;81(6):940-2. doi: 10.1111/cen.12519. Epub 2014 Jul 2.
6
Severe hypocalcemia after denosumab in a patient with acquired Fanconi syndrome.一名获得性范科尼综合征患者使用地诺单抗后出现严重低钙血症。
Osteoporos Int. 2014 Mar;25(3):1187-90. doi: 10.1007/s00198-013-2533-0. Epub 2013 Oct 25.
7
Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer.地舒单抗治疗转移性去势抵抗性前列腺癌后低钙血症持续时间延长。
Bone. 2013 Aug;55(2):305-8. doi: 10.1016/j.bone.2013.04.012. Epub 2013 Apr 25.
8
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.地舒单抗优于唑来膦酸预防骨骼相关事件：3 项关键性、随机、3 期临床试验的联合分析。
Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.
9
Japanese classification of gastric carcinoma: 3rd English edition.日本胃癌分类：第3版英文版
Gastric Cancer. 2011 Jun;14(2):101-12. doi: 10.1007/s10120-011-0041-5.
10
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.地舒单抗对比唑来膦酸治疗去势抵抗性前列腺癌骨转移患者的随机、双盲研究。
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.